← Back to Search

Gene Therapy

beta thalassemia for Beta Thalassemia

Phase 1 & 2

Waitlist Available

Led By Janet Kwiatkowski, MD

Research Sponsored by Children's Hospital of Philadelphia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year after infusion

Awards & highlights

Study Summary

This trial aims to investigate whether a new treatment method can safely help patients with a blood disorder called transfusion-dependent beta thalassemia. The treatment involves modifying blood stem cells by adding a healthy

Who is the study for?

This trial is for individuals with transfusion-dependent beta thalassemia, a blood disorder. Participants must have a history of needing regular blood transfusions. Specific eligibility criteria are not provided, but typically include factors like age range, overall health status, and the severity of the condition.Check my eligibility

What is being tested?

The study is testing an experimental gene therapy called CHOP-ALS20 (study drug) to treat beta thalassemia by modifying patients' own blood stem cells with a healthy beta globin gene and returning them to the patient's body.See study design

What are the potential side effects?

Since this is the first time CHOP-ALS20 is being tested in humans, potential side effects are unknown. However, common risks may include immune reactions, infection risk from procedures, or complications related to stem cell transplantation.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year after infusion

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year after infusion

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year after infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Clonal Predominance

Incidence of Graft Versus Host Disease

Incidence of Vector-Derived Replication Competent Lentivirus

+6 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: beta thalassemiaExperimental Treatment1 Intervention

This arm will evaluate the safety and efficacy of infusing autologous hematopoietic stem and progenitor cells (HSPC) transduced with the novel lentiviral vector ALS20 that encodes the human βA-T87Q-globin gene, following myeloablative conditioning with busulfan.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Children's Hospital of PhiladelphiaLead Sponsor

709 Previous Clinical Trials

8,583,030 Total Patients Enrolled

Janet Kwiatkowski, MDPrincipal InvestigatorChildren's Hospital of Philadelphia

6 Previous Clinical Trials

1,091 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this medical study include individuals who are older than 35 years of age?

"Individuals aged between 18 and 35 years are eligible for enrollment in this clinical trial."

Answered by AI

Are individuals currently able to apply and participate in this ongoing research study?

"Following the details provided on clinicaltrials.gov, it appears that recruitment for this particular study has concluded. The trial was initially listed on May 1st, 2024, with its latest update recorded on April 11th of the same year. While this specific study is no longer accepting participants, there are currently 73 alternative trials open for enrollment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia

2024. "ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06364774.

All > Thalassemia